Taipan - Empfehlungen im Netz ? - 500 Beiträge pro Seite
eröffnet am 01.11.02 14:55:05 von
neuester Beitrag 20.11.02 20:43:41 von
neuester Beitrag 20.11.02 20:43:41 von
Beiträge: 12
ID: 654.413
ID: 654.413
Aufrufe heute: 0
Gesamt: 776
Gesamt: 776
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 01.05.24, 18:36 | 1090 | |
| gestern 22:25 | 348 | |
| heute 00:17 | 245 | |
| gestern 23:38 | 216 | |
| heute 00:00 | 143 | |
| heute 01:50 | 106 | |
| gestern 23:59 | 102 | |
| gestern 23:53 | 96 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.001,60 | +0,59 | 240 | |||
| 2. | 2. | 181,19 | +0,66 | 87 | |||
| 3. | 3. | 9,7000 | +12,27 | 75 | |||
| 4. | 14. | 6,1400 | -1,35 | 69 | |||
| 5. | 11. | 0,1865 | 0,00 | 52 | |||
| 6. | 7. | 0,8750 | -12,50 | 47 | |||
| 7. | 12. | 0,1561 | +2,97 | 38 | |||
| 8. | 6. | 2.302,50 | 0,00 | 36 |
Feedback
Weiss jemand ob aktuelle Taipan Empfehlungen im Netz zu finden sind?
Ich bekam mal eine Probeausgabe und bin fasziniert...
Ich bekam mal eine Probeausgabe und bin fasziniert...
wie sieht´s mit ner antwort aus ?
ich warte noch
glaube net dass man offiziell Taipan irgendwo im Netz findet!!
aber du hast mit Virologic eine gute Wahl getroffen!!
die lasse ich mittel- bis langfristig auf jeden Fall im Depot liegen.
die story ist phantastisch. die Produktpipeline auch!!
aber du hast mit Virologic eine gute Wahl getroffen!!
die lasse ich mittel- bis langfristig auf jeden Fall im Depot liegen.
die story ist phantastisch. die Produktpipeline auch!!
werde ich genauso machen,
lasse sie länger im depot und hohe kurse werden kommen!
gruß.
lasse sie länger im depot und hohe kurse werden kommen!
gruß.
Trading Spotlight
@all
morgen 12.11.2002 5:00 PM, QIII Zahlen bei Virologic - gleichzeitig Chat mit den Vorstand. Mehr Informationen unter www.virologic.com
Mfg
André
P.S. Hoffen wir das beste!
morgen 12.11.2002 5:00 PM, QIII Zahlen bei Virologic - gleichzeitig Chat mit den Vorstand. Mehr Informationen unter www.virologic.com
Mfg
André
P.S. Hoffen wir das beste!
danke andré!
da kommen huete bestimmt gute News!!
gestern zog der Kurs schon 18% auf 1,20$ an
!!!
alles wurde weggekauft am Ende....Insider??
hoffen wir das Beste!!
gestern zog der Kurs schon 18% auf 1,20$ an
!!!alles wurde weggekauft am Ende....Insider??
hoffen wir das Beste!!
ViroLogic Signs Preferred Provider Agreement and Equity Agreement with Pfizer
11/14/02
SOUTH SAN FRANCISCO, Calif., Nov 14, 2002 /PRNewswire-FirstCall via COMTEX/ --
ViroLogic, Inc. (Nasdaq: VLGC) announced today that the Company has signed a preferred provider agreement with Pfizer Inc. (NYSE: PFE).
Under the terms of the agreement, ViroLogic becomes Pfizer`s preferred supplier for HIV resistance testing technology and services to support Pfizer`s HIV drug discovery and development programs, and Pfizer will guarantee undisclosed service minimums for a period of three years. In addition Pfizer will make an equity investment in ViroLogic resulting in their ownership of approximately 5% of the Company.*
ViroLogic has developed technologies to assess drug resistance among a number of antiretroviral therapies in both preclinical and clinical studies including PhenoSense(TM) HIV, GeneSeq(TM), PhenoSenseGT(TM), PhenoSense HIV Entry(TM) and PhenoScreen(TM).
na da wird der kurs heute anziehen.
grüße t.1
11/14/02
SOUTH SAN FRANCISCO, Calif., Nov 14, 2002 /PRNewswire-FirstCall via COMTEX/ --
ViroLogic, Inc. (Nasdaq: VLGC) announced today that the Company has signed a preferred provider agreement with Pfizer Inc. (NYSE: PFE).
Under the terms of the agreement, ViroLogic becomes Pfizer`s preferred supplier for HIV resistance testing technology and services to support Pfizer`s HIV drug discovery and development programs, and Pfizer will guarantee undisclosed service minimums for a period of three years. In addition Pfizer will make an equity investment in ViroLogic resulting in their ownership of approximately 5% of the Company.*
ViroLogic has developed technologies to assess drug resistance among a number of antiretroviral therapies in both preclinical and clinical studies including PhenoSense(TM) HIV, GeneSeq(TM), PhenoSenseGT(TM), PhenoSense HIV Entry(TM) and PhenoScreen(TM).
na da wird der kurs heute anziehen.
grüße t.1
ViroLogic Announces Third Quarter 2002 Financial Results
11/14/02
Signs Definitive Agreements with Pfizer and Other Investors for Additional $10 Million in Cash; Reduces Burn Rate and Focuses Resources On Revenue-Maximizing Activities
SOUTH SAN FRANCISCO, Calif., Nov 14, 2002 /PRNewswire-FirstCall via COMTEX/ --
ViroLogic, Inc. (Nasdaq: VLGC) today reported financial results for the third quarter ended September 30, 2002.
The Company also announced that it has signed definitive agreements to raise an additional $10 million in cash, including equity investments from Pfizer Inc. and a group of investors comprised of existing and new stockholders. In addition the Company has entered into a preferred provider agreement with Pfizer for ViroLogic`s HIV drug resistance tests and services.
"We believe the agreements with Pfizer and other investors validate the value of our technology and business," said Bill Young, CEO and Chairman of ViroLogic. "We continue to build a base in our patient testing business with potential future growth coming from our combination phenotypic/genotypic test, and the introduction of our replication capacity assay. Our drug development business, though currently subject to delays of large clinical trials that were anticipated to start in the third and fourth quarters of this year, remains strong, with those trials expected to begin early next year. We also have an additional source of income by offering analyses from our proprietary HIV drug resistance database. On the expense side, we are substantially reducing our burn rate to focus resources on revenue-maximizing activities and to help us reach our goal of becoming cash-flow positive."
Third Quarter Financial Results Summary
The Company reported revenue of $5.9 million for the third quarter of 2002, an increase of 35 percent compared to revenue of $4.4 million for the same period in 2001. Gross margin was 39 percent in the third quarter of 2002, compared to 36 percent in the third quarter of 2001. Operating costs and expenses for the third quarter of 2002 were $11.5 million, compared to $11.1 million for the same period in 2001. The increase primarily reflects higher testing volume and increased sales and marketing activities to support new product launches. This increase was partially offset by a reduction in research and development activities and related expenses.
Net loss was $5.6 million, or $0.23 per share, for the third quarter of 2002, compared to a net loss of $6.6 million, or $0.33 per share, for the same period in 2001. In the third quarter of 2002, the Company recorded a preferred stock dividend of $0.2 million resulting in a net loss applicable to common stockholders of $0.24 per common share. During the third quarter of 2001, the Company recorded a deemed dividend to preferred stockholders of $2.3 million and a preferred stock dividend of $0.1 million resulting in a net loss applicable to common stockholders of $0.45 per share.
ViroLogic to Raise Additional Cash
The Company expects to raise $10 million from the Pfizer equity investment and private financings, which are subject to closing conditions and expected to close by November 19, 2002. In addition, the Company is scheduled to receive another $1 million in cash from an assignment of a lease of one of the Company`s buildings, a transaction that was announced last quarter. The Company had $6.2 million of cash, restricted cash and short-term investments as of September 30, 2002.
2002 Outlook, Cost-Cutting Moves to Reduce Burn
Based primarily on the delay in the start of new clinical trials on the drug development side of its business, the Company has revised its year-end revenue forecast to $24 to $26 million from $28 to $32 million. The Company expects to start generating the revenues from these trials in early 2003 instead of in the third and fourth quarters of 2002 as originally anticipated. Because of these delays and in an effort to reduce its burn rate, ViroLogic will reduce its workforce by approximately 20 percent, or about 40 employees. The Company will also reduce officer salaries and consolidate certain operations, including sales and marketing under Tien Bui, who will become Vice President of Sales and Marketing.
The Company anticipates taking a charge in the fourth quarter associated with these actions of about $0.4 million. These actions should reduce the historical burn rate of about $6 million per quarter by approximately $1.5 million in the first quarter of 2003. The burn rate is expected to decrease with revenue growth in subsequent quarters.
Recent Highlights
-- Entered agreement with Surveillance Data, Inc. (SDI) to create new line
of HIV market research products based on ViroLogic`s database.
-- Created significant presence at 42nd Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC), including several
presentations related to both new and existing ViroLogic products and
technology, and a symposium entitled "Evolving Issues in HIV Drug
Resistance: Strategies for Individualized HIV Treatment."
-- Studies using/highlighting ViroLogic`s technology published in New
England Journal of Medicine (NEJM) and Journal of Acquired Immune
Deficiency Syndromes (JAIDS). The NEJM study strongly supports
resistance testing for newly infected individuals and the JAIDS study
demonstrates the potential clinical benefit of using phenotypic and
genotypic HIV-1 drug resistance assays together, i.e. PhenoSenseGT(TM)
11/14/02
Signs Definitive Agreements with Pfizer and Other Investors for Additional $10 Million in Cash; Reduces Burn Rate and Focuses Resources On Revenue-Maximizing Activities
SOUTH SAN FRANCISCO, Calif., Nov 14, 2002 /PRNewswire-FirstCall via COMTEX/ --
ViroLogic, Inc. (Nasdaq: VLGC) today reported financial results for the third quarter ended September 30, 2002.
The Company also announced that it has signed definitive agreements to raise an additional $10 million in cash, including equity investments from Pfizer Inc. and a group of investors comprised of existing and new stockholders. In addition the Company has entered into a preferred provider agreement with Pfizer for ViroLogic`s HIV drug resistance tests and services.
"We believe the agreements with Pfizer and other investors validate the value of our technology and business," said Bill Young, CEO and Chairman of ViroLogic. "We continue to build a base in our patient testing business with potential future growth coming from our combination phenotypic/genotypic test, and the introduction of our replication capacity assay. Our drug development business, though currently subject to delays of large clinical trials that were anticipated to start in the third and fourth quarters of this year, remains strong, with those trials expected to begin early next year. We also have an additional source of income by offering analyses from our proprietary HIV drug resistance database. On the expense side, we are substantially reducing our burn rate to focus resources on revenue-maximizing activities and to help us reach our goal of becoming cash-flow positive."
Third Quarter Financial Results Summary
The Company reported revenue of $5.9 million for the third quarter of 2002, an increase of 35 percent compared to revenue of $4.4 million for the same period in 2001. Gross margin was 39 percent in the third quarter of 2002, compared to 36 percent in the third quarter of 2001. Operating costs and expenses for the third quarter of 2002 were $11.5 million, compared to $11.1 million for the same period in 2001. The increase primarily reflects higher testing volume and increased sales and marketing activities to support new product launches. This increase was partially offset by a reduction in research and development activities and related expenses.
Net loss was $5.6 million, or $0.23 per share, for the third quarter of 2002, compared to a net loss of $6.6 million, or $0.33 per share, for the same period in 2001. In the third quarter of 2002, the Company recorded a preferred stock dividend of $0.2 million resulting in a net loss applicable to common stockholders of $0.24 per common share. During the third quarter of 2001, the Company recorded a deemed dividend to preferred stockholders of $2.3 million and a preferred stock dividend of $0.1 million resulting in a net loss applicable to common stockholders of $0.45 per share.
ViroLogic to Raise Additional Cash
The Company expects to raise $10 million from the Pfizer equity investment and private financings, which are subject to closing conditions and expected to close by November 19, 2002. In addition, the Company is scheduled to receive another $1 million in cash from an assignment of a lease of one of the Company`s buildings, a transaction that was announced last quarter. The Company had $6.2 million of cash, restricted cash and short-term investments as of September 30, 2002.
2002 Outlook, Cost-Cutting Moves to Reduce Burn
Based primarily on the delay in the start of new clinical trials on the drug development side of its business, the Company has revised its year-end revenue forecast to $24 to $26 million from $28 to $32 million. The Company expects to start generating the revenues from these trials in early 2003 instead of in the third and fourth quarters of 2002 as originally anticipated. Because of these delays and in an effort to reduce its burn rate, ViroLogic will reduce its workforce by approximately 20 percent, or about 40 employees. The Company will also reduce officer salaries and consolidate certain operations, including sales and marketing under Tien Bui, who will become Vice President of Sales and Marketing.
The Company anticipates taking a charge in the fourth quarter associated with these actions of about $0.4 million. These actions should reduce the historical burn rate of about $6 million per quarter by approximately $1.5 million in the first quarter of 2003. The burn rate is expected to decrease with revenue growth in subsequent quarters.
Recent Highlights
-- Entered agreement with Surveillance Data, Inc. (SDI) to create new line
of HIV market research products based on ViroLogic`s database.
-- Created significant presence at 42nd Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC), including several
presentations related to both new and existing ViroLogic products and
technology, and a symposium entitled "Evolving Issues in HIV Drug
Resistance: Strategies for Individualized HIV Treatment."
-- Studies using/highlighting ViroLogic`s technology published in New
England Journal of Medicine (NEJM) and Journal of Acquired Immune
Deficiency Syndromes (JAIDS). The NEJM study strongly supports
resistance testing for newly infected individuals and the JAIDS study
demonstrates the potential clinical benefit of using phenotypic and
genotypic HIV-1 drug resistance assays together, i.e. PhenoSenseGT(TM)
Von Taipan halte ich überhaupt nichts! Die haben nur damals in der allgemeinen Börsenhype-Zeit gute Empfehlungen auf exotische Aktien abgegeben. War damals zu Aktien-Boomzeiten auch nicht schwer. Außerdem wählt Taipan fast ausschließlich Aktien mit geringen täglich gehandelten Stückzahlen aus. Da können die leicht selber mit ein paar kleineren Käufen den Kurs hochtreiben und Kleinaktionäre abzocken.
Was auch dubios ist, das das Magazin aus der gleichen Adresse in Grebenau kommt wie z.B. auch andere Käseblätter wie Sicheres Geld von Martin Weiss. Und immer wieder taucht als Herausgeberin der Magazine Sandra Witscher auf. Schon sehr dubios!
Was auch dubios ist, das das Magazin aus der gleichen Adresse in Grebenau kommt wie z.B. auch andere Käseblätter wie Sicheres Geld von Martin Weiss. Und immer wieder taucht als Herausgeberin der Magazine Sandra Witscher auf. Schon sehr dubios!
Wer trotzdem was von Taipan noch lesen möchte:
www.taipan-online.de
www.taipan-online.de
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 237 | ||
| 90 | ||
| 76 | ||
| 67 | ||
| 52 | ||
| 48 | ||
| 37 | ||
| 35 | ||
| 32 | ||
| 31 |
| Wertpapier | Beiträge | |
|---|---|---|
| 28 | ||
| 27 | ||
| 24 | ||
| 23 | ||
| 23 | ||
| 20 | ||
| 20 | ||
| 20 | ||
| 15 | ||
| 13 |
